AUG 21, 2014 08:45 AM PDT

From Genetics to Genetic Medicine: Gene Therapy for vision restoration as a case study

Speakers
  • Assistant Professor, Harvard Medical School, Assistant Scientist, Schepens Eye Research Institute, Massachusetts Eye and Ear
    Biography
      Assistant Professor, Harvard Medical School
      <br />Assistant Scientist, Schepens Eye Research Institute, Massachusetts Eye and Ear
      <br />Director, Gene Transfer Vector Core (GTVC)
      <br />Associate Director, Ocular Genomics Institute (OGI)
      <br />Investigator, Berman-Gund Laboratory for Retinal Degenerations, Howe Laboratory
      <br />Affiliate Faculty, Harvard Stem Cell Institute
      <br />
      <br />Luk H. Vandenberghe, PhD, trained as a biochemical engineer through his training at the University in Leuven, Belgium where he later also obtained his doctoral degree in Medical Sciences. Most of his graduate and postdoctoral work was performed at the University of Pennsylvania in Philadelphia in the leading gene therapy laboratories of Carl June, James Wilson, and Jean Bennett. In 2012, Dr. Vandenberghe set up a lab at the Schepens Eye Research Institute and Mass Eye and Ear in Boston where he is Assistant Professor at Harvard Medical School. Currently he is Director of the Grousbeck Gene Therapy Center and Associate Director of the Ocular Genomics Institute, both primarily focused at bringing gene therapies for vision restoration to the clinic.
      <br />
      <br />In previous work Dr. Vandenberghe has co-discovered, developed, and characterized novel serotypes of the adeno-associated virus (including AAV8,9), several of which are now in wide use at preclinical and clinical experimental stages for a host of target tissues and indications. His work has elucidated key insights into the host response of AAV in humans in the context of pre-existing immunity of this virus endemic in humans. Dr. Vandenberghe is a co-founder of a biotechnology company called GenSight Biologics (Paris, France) and named inventor in over a dozen published and pending patents of gene therapy related technologies.
      <br />
      <br />The Vandenberghe lab at Harvard studies gene therapy approaches for neurosensory disorders with a focus on clinical programs for retinal dystrophies. Its broader ambition is to make gene therapy a widely applicable clinical modality in ophthalmology and beyond. Toward this goal his program builds innovative vector technologies to overcome current translational hurdles.&nbsp; His research brings together molecular virology and immunology, synthetic biology, engineering, and medicine in attempt to understand and improve the challenges of the therapeutic potential of in vivo gene transfer.
      <br />

    Abstract:

    Gene therapy for two forms of inherited retinal degeneration have met promising safety and efficacy endpoints in early stage clinical trials. These approaches made use of a replication defective virus or vector based on the adeno-associated virus type 2 (AAV2), a small non enveloped ssDNA virus endemic in human population. AAV2 targets the retinal pigment epithelium (RPE) at high efficiency in small and large animal models, which is the primary target in these studies. Retinal disease however has a range of etiologies and cell types at the basis of its pathogenesis, and a broader set of tools to deliver therapeutic genes to the retina is required. Here, we describe our past and current efforts to develop novel vectors and therapeutic strategies to unlock genetic treatment for retinal blinding disorders.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    Loading Comments...
    Show Resources